Drug intelligence / Profile preview

ebvaciclib

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Ebvaciclib (PF-06873600) is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinase 2, 4, and 6 (CDK2/4/6), developed for the treatment of cancer. By selectively targeting and inhibiting these CDKs, ebvaciclib disrupts cell cycle progression—leading to cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation. CDKs are ATP-dependent serine/threonine kinases that regulate the cell cycle and are often overexpressed in tumor cells. Ebvaciclib has shown potential antineoplastic activity in preclinical models and is being investigated in clinical trials for various cancers[1][3][5][7].

Other names: ebvaciclib

Targets

CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on ebvaciclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ebvaciclib.

Explore the full profile